A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Trial Profile

A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Plantar fasciitis
  • Focus Therapeutic Use
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 03 Nov 2017 According to a Revance Therapeutics media release, company will report topline 8-week safety and efficacy results at year-end.
    • 18 Oct 2017 According to a Revance Therapeutics media release, company anticipates to report top line data before year end.
    • 18 Oct 2017 Status changed from recruiting to active, no longer recruiting, according to a Revance Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top